CARTITUDE-2NCT04133636
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 87 versions: 29 with changes below, 21 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 24 words
- Secondary endpoints: details revised at 7 of 24 entries
- Site details revised at 1 of 47 sites
- Notable Primary completion pushed from Aug 4, 2026 to Feb 26, 2027
- Study completion moved earlier from Sep 3, 2029 to Aug 25, 2028
- Notable Primary endpoint(s) modified
- Eligibility criteria expanded, about 9 words
- Enrollment target: 210 to 208
- Secondary endpoints: 23 to 24
- Minor Site details revised at 1 of 47 sitesv81
- Minor Study completion date: Jan 17, 2028 to Sep 3, 2029v79
Show 24 earlier versionsHide 24 earlier versions
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 237 to confirmed 210
- Site details revised at 47 of 47 sites
- Minor Site details revised at 1 of 47 sitesv76
- Notable Primary completion date: Dec 1, 2025 to Aug 4, 2026
- Study completion date: Nov 13, 2028 to Jan 17, 2028
- Minor Site details revised at 4 of 47 sitesv73
- Minor Site details revised at 1 of 47 sitesv68
- Minor Study sites: 46 to 47v65
- Minor Study sites: 44 to 46v63
- Minor Study sites: 42 to 44v61
- Minor Study sites: 41 to 42v60
- Minor Study sites: 39 to 41v59
- Minor Site details revised at 10 of 39 sitesv58
- Notable Trial status: Active, Not Recruiting to Recruiting
- Enrollment target: 169 to 237
- Study sites: 37 to 39
- Notable Primary completion date: May 30, 2025 to Dec 1, 2025
- Study sites revised (37)
- Minor Study sites: 33 to 37v55
- Minor Study sites revised (33)v53
- Minor Study sites revised (33)v50
- Minor Study completion date: Jun 10, 2027 to Nov 13, 2028
- Study sites revised (33)
- Minor Study completion date: May 30, 2025 to Jun 10, 2027
- Site details revised at 1 of 33 sites
- Minor Site details revised at 1 of 33 sitesv44
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 157 to confirmed 169
- Site details revised at 33 of 33 sites
- Notable Primary completion date: Aug 1, 2024 to May 30, 2025
- Site details revised at 28 of 33 sites
- Minor Study sites: 43 to 33v40
- Minor Study completion date: Feb 25, 2026 to May 30, 2025v39
- Minor Study sites revised (43)v38
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (24)
Show 19 moreShow less
Arms and interventions
Single group assignment-Post lymphodepletion, JNJ-68284528 single infusion given to Part A participants: Cohort A (Progressive disease post 1-3 prior lines of therapy), Cohort B (Early relapse post front-line), Cohort C(Relapsed/refractory multiple myeloma post PI, IMiD,anti-CD38,anti-BCMA therapy), Cohort D(Less than CR post ASCT front-line therapy, some participants will receive JNJ-68284528 then lenalidomide), Cohort F(Newly diagnosed multiple myeloma \[NDMM\], standard risk \[International Staging System Stage I/II\] and post initial therapy); Cohort E(NDMM,transplant not planned, high risk disease) will first receive quadruplet induction regimen of daratumumab, bortezomib, lenalidomide and dexamethasone(D-VRd) then lymphodepletion and JNJ-68284528 then consolidation regimen of lenalidomide. Enrollment is closed for Cohorts A,B,C,D,E and F. For US sites only: Part B:Cohort G (NDMM, transplant not planned) will receive daratumumab, lenalidomide and dexamethasone followed by cilta-cel.
Drugs: JNJ-68284528, Lenalidomide, Daratumumab, Bortezomib, Dexamethasone
Sites
47 sites in 8 countries
United States 33, France 3, Belgium 2, Germany 2, Israel 2, Netherlands 2, Spain 2, Saudi Arabia 1